Ken Griffin Allakos Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Allakos Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 30,300 shares of ALLK stock, worth $38,481. This represents 0.0% of its overall portfolio holdings.
Number of Shares
30,300
Previous 12,400
144.35%
Holding current value
$38,481
Previous $12,000
58.33%
% of portfolio
0.0%
Previous 0.0%
Shares
23 transactions
Others Institutions Holding ALLK
# of Institutions
81Shares Held
64.7MCall Options Held
47.1KPut Options Held
1K-
Bvf Inc San Francisco, CA16.6MShares$21 Million0.34% of portfolio
-
Nea Management Company, LLC Timonium, MD6.15MShares$7.81 Million0.31% of portfolio
-
Deep Track Capital, LP Greenwich, CT5MShares$6.35 Million0.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.51MShares$4.46 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA3.08MShares$3.91 Million0.13% of portfolio
About Allakos Inc.
- Ticker ALLK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 84,726,096
- Market Cap $108M
- Description
- Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...